Singapore Volition Pte. Ltd, a wholly-owned subsidiary of VolitionRx Limited (NYSE American: VNRX) (“Volition”), has entered into a Memorandum of Understanding (“MOU”) with the National Taiwan University (“NTU”) to conduct two large colorectal cancer (CRC) research studies across the Asia Pacific Region, totaling approximately 7,000 patient samples. Subject to agreement on the terms and conditions, the Parties intend to sign a binding CRC Study Agreement in the first quarter of 2018.
“The signing of this MOU is a good start for Volition in the Asia Pacific Region” commented Dr. Jasmine Kway, Volition’s Vice President of Asia. “We are fortunate and delighted to be working with a renowned institution and Professor Han-Mo Chiu, a prominent thought leader. This large-scale study will be low cost in line with Volition’s other great value studies such as the 13,500-subject study in the U.S. and the ongoing 30,000-subject prospective study in Europe and demonstrates our commitment to conducting large trials worldwide to drive the acceptance of our products.”
The first trial will be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific Region, including 5,000 asymptomatic colorectal cancer screening subjects. The second trial will include up to 2,000 symptomatic colorectal cancer patients. These studies are being conducted to test and validate Volition’s proprietary Nu.QTM platform for the detection and diagnosis of colorectal cancer for marketing, rather than for regulatory purposes.
The studies will be under the supervision of Professor Han-Mo Chiu, Clinical Professor, Department of Internal Medicine of NTU who will be the Principal Investigator for both trials. Prof. Chiu is highly regarded and widely published in this field, with many awards and achievements to his name. Professor Chiu commented, “The early detection of colorectal cancer could benefit the survival rate of patients significantly. There is a clear need for a product which not only has high accuracy but is also easy to use and affordable. I look forward to proceeding with the collaboration with Volition on these projects.”
About the National Taiwan University
NTU is one of the most prestigious universities in the world and is the top university in Taiwan. The University has a wide network of partners and collaborators and plays a leading role in education and research. The University has four university level research centers, with an overall student population of 33,000.
About Volition
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition’s website (http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition’s website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition’s website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
|
